5-溴水杨酰胺 | 6329-74-4

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴水杨酰胺
• 中文别名: 苯甲酰胺,5-溴-2-羟基
• 英文名称: 5-bromo-2-hydroxybenzamide
• 英文别名: 5-bromosalicylamide
• CAS: 6329-74-4
• 化学式: C₇H₆BrNO₂
• mdl: MFCD00157694
• 分子量: 216.034
• InChiKey: MRMOPHYFXXZTFN-UHFFFAOYSA-N

物化性质

• 熔点：
  241-245 °C(lit.)
• 沸点：
  316.6±32.0 °C(Predicted)
• 密度：
  1.759±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险发生。应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S28,S36/37
• 危险类别码：
  R22,R43
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  请将药品存放在密闭、阴凉干燥的地方，并保持良好通风。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromosalicylamide
Synonyms: 5-Bromo-2-hydroxybenzamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromosalicylamide
CAS number: 6329-74-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BrNO2
Molecular weight: 216.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

5-溴水杨酰胺是一种酰胺类有机物，可用作医药合成中间体。

制备方法

在100 mL圆底烧瓶中，将1.5 g（0.011 mol）水杨酰胺溶解于21.9 mL冰醋酸中。室温下缓慢滴加0.556 mL（0.011 mol）液溴的冰醋酸溶液，并搅拌反应。通过TLC跟踪反应至终点，随后将产物倒入冷水中，析出大量白色固体。

反应信息

• 作为反应物：
  描述：

  5-溴水杨酰胺 在 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 四丁基硫酸氢铵 、 sodium hydride 、 potassium carbonate 、 sodium hydroxide 作用下， 以 N,N-二甲基乙酰胺 、 醋酸异丙酯 、 水 、 甲苯 为溶剂， 生成 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
  参考文献：
  名称：

  PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS

  摘要：

  本公开提供了制备以下化合物的过程：这是一种选择性晚期钠电流抑制剂。该公开还提供了合成中间体化合物。

  公开号：

  US20150225384A1
• 作为产物：
  描述：

  水杨酸苯酯 在 氨 、 溴 、 溶剂黄146 作用下， 生成 5-溴水杨酰胺
  参考文献：
  名称：

  Kauschke, Journal fur praktische Chemie (Leipzig 1954), 1895, vol. <2> 51, p. 212

  摘要：

  DOI：

文献信息

• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• Process Development and Scale-Up of a Benzoxazepine-Containing Kinase Inhibitor
  作者：Sriram Naganathan、Denise L. Andersen、Neil G. Andersen、Stephen Lau、Anders Lohse、Mads Detlef Sørensen

  DOI：10.1021/acs.oprd.5b00037

  日期：2015.7.17

  The benzoxazepine core is present in several kinase inhibitors, including the mTOR inhibitor 1. The process development for a scalable synthesis of 7-bromobenzoxazepine and the telescoped synthesis of 1 are reported. Compound 1 consists of three chemically rich, distinct fragments: the tetrahydrobenzo[f][1,4]oxazepine core, the aminopyridyl fragment, and the substituted (methylsulfonyl)benzoyl fragment

  苯并x氮平核心存在于几种激酶抑制剂中，包括mTOR抑制剂1。报道了7-溴苯并x杂的可扩展合成和1的伸缩合成的方法开发。化合物1由三个化学含量丰富的独特片段组成：四氢苯并[ f ] [1,4]氧杂氮杂核，氨基吡啶基片段和取代的（甲基磺酰基）苯甲酰基片段。开发了制备3-氟-2-甲基-4-（甲基磺酰基）苯甲酸（17）和叔丁基7-溴-2,3-二氢苯并[ f ] [1,4]氧杂氮平-4（17）的方法。 5 H）-羧酸盐（2）。扩大了这两种化合物的生产规模，每种原料的制备量均超过15 kg，总收率分别为42％和58％。以化合物2开头的伸缩序列，以63％的收率得到7.5千克精细的中间体5-（2,3,4,5-四氢苯并[ f ] [1,4]恶唑啉-2-胺二盐酸盐（6）。用苯甲酸17用7.6 ％的目标化合物1的收率为84％，最终制得了优选的盐酸盐，在8个分离的合成步骤中，合成抑制剂1的总收率为21％，最终得到了盐。
• [EN] N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE APPARENTÉS À LA N-ACYLPIPÉRIDINE ÉTHER TROPOMYOSINE
  申请人：PFIZER LTD

  公开号：WO2015092610A1

  公开（公告）日：2015-06-25

  The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.

  本发明涉及本文所述的式(I)化合物及其药学上可接受的盐，以及它们在医学上的用途，特别是作为Trk拮抗剂。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• Synthesis and Biological Activity of Novel 1,3-Benzoxazine Derivatives as K+ Channel Openers.
  作者：Satoshi YAMAMOTO、Shohei HASHIGUCHI、Shokyo MIKI、Yumiko IGATA、Toshifumi WATANABE、Mitsuru SHIRAISHI

  DOI：10.1248/cpb.44.734

  日期：——

  A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant

  设计了一系列在C4处带有2-吡啶1-氧化物基团的1,3-苯并恶嗪衍生物新系列，以探索新型的K +通道开放剂。通过使用亚氨基三氟甲磺酸的钯（0）催化的碳-碳键形成反应与有机锌试剂进行合成，并通过新的一锅一锅的苯甲酰基吡啶的1,3-苯并恶嗪骨架形成反应进行合成。测试了这些化合物在四乙基氯化铵（TEA）中的血管舒张活性，以及​​BaCl2诱导的和高KCl诱导的大鼠主动脉收缩，以确定潜在的K +通道开放剂，以及在自发性高血压大鼠中的口服降压作用。1,3-苯并恶嗪核的C6处具有适当形状的吸电子基团和C7处具有甲基或卤代基团是开发最佳血管舒张剂和降血压活性所必需的。特别是，

表征谱图